NUCLEUS-SOFTWARE
5.10.2021 15:09:13 CEST | Business Wire | Press release
Opel Vauxhall Finance announces the going live in Spain of Nucleus Software’s flagship lending product, FinnOne. Nucleus Software is the leading provider of lending and transaction banking products and solutions to the global financial industry. Spain becomes the ninth European country for Opel Vauxhall Finance (OVF) to go live with FinnOne.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005757/en/
OVF is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution.
While FinnOne has been supporting businesses for Opel Vauxhall Finance in Europe since 2006, Spain is the latest country that will run OVF business using FinnOne. The OVF FinnOne partnership began in Italy and then moved on to Belgium, Netherlands, UK, France, Germany, Austria and Switzerland. The OVF portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts.
Opel Vauxhall Finance wanted to utilize its core applications to achieve economies of scale. Nucleus Software FinnOne SRS (Strategic Retail Solution) is helping OVF in leveraging existing functionalities and aligning Spanish business processes to the OVF strategic applications rather than customizing and increasing scope & cost.
“With FinnOne going live in Spain, Opel Vauxhall Finance will be able to improve operational efficiency and align with the corporate strategic technology framework. With enhanced digitization, we will also be able to strengthen the collaboration framework with Opel/Vauxhall to increase the volume of financed/leased vehicles while at the same time raising retail margins across Europe,” says Alexandre Sorel, CEO of Opel Vauxhall Finance.
“We are proud to continue to bring value to our long-term partnership with Opel Vauxhall Finance (OVF). Spain is the ninth European country where FinnOne is supporting OVF in running their complex business. Having a common solution running across nine countries provides a competitive edge to OVF in terms of operational efficiency, uniform rollouts and standardization. We were able to go live despite the pandemic by meeting business commitments thanks to the coming together of OVF and Nucleus teams using our deep expertise in off-shore implementation methodology,” says Parag Bhise, CEO, Nucleus Software.
About Opel Vauxhall Finance:
OVF (Opel Vauxhall Finance) is the automotive finance captive organization of Opel and Vauxhall, supported by Stellantis and BNP Paribas, taken over from GM Financial in 2017. OVF trades under strong local brands such as Opel Bank, Opel Financial Services and Vauxhall Finance. OVF has multiple operational branches across Europe, each operating under local bank licence or Financial Institution. For IT Operations, everything is controlled from UK under the name Opel Vauxhall Finance.
Its portfolio includes a wide range of auto financing products, including consumer loans, leasing, insurance and service contracts as well as dealer financing. In Germany, OVF also offer money market accounts and fixed-term deposits directly to end-consumers, complementing our traditional automotive finance business.
OVF's primary goal is to meet the mobility needs of customers across Europe, while sustaining and developing the Opel and Vauxhall brands through competitive and attractive automotive finance solutions. Financing Opel and Vauxhall Brands dates back to 1920 when it opened its first office in London, helping people in the UK to finance their vehicles. In 1929 Opel Finanzierungsgesellschaft mbH was founded in Russelsheim, Germany, as the strategic finance partner for Opel.
About Nucleus Software:
Nucleus Software Exports Ltd. is a publicly traded (BSE: 531209, NSE: NUCLEUS) software product company that provides lending and transaction banking products to global financial leaders.
Nucleus Software powers the operations of more than 200 Financial Institutions in over 50 countries, supporting retail lending, corporate banking, cash management, mobile and internet banking, automotive finance and other business areas. Its products facilitate more than 26 million transactions each day, managing over US $200 billion of loans and enabling more than 200,000 users logging in daily.
For more information, please visit: www.nucleussoftware.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005757/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 14:30:00 CEST | Press release
Public equities have re-emerged as the primary destination for incremental capital Private markets remain a strategic pillar of family office portfolios Artificial intelligence is moving from experimentation toward implementation Cross-border complexity is rising as families become increasingly international Leadership succession and next-generation preparedness are now immediate priorities rather than distant considerations Watch Citi Wealth’s Global Family Office leadership discuss the report’s findings here. Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Tod
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 14:30:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom